News2025-10-09T17:32:10+00:00
News
Home»Company»News

News

Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.

1212, 2023

The FDA’s approval of Casgevy and Lyfgenia represents a transformative moment in the evolution of gene therapy

December 12th, 2023|

In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has approved two revolutionary treatments, Casgevy and Lyfgenia, marking a significant milestone in the field of gene therapy. These therapies represent the first-ever cell-based gene treatments for sickle cell disease (SCD) in patients...

2711, 2023

Gene Therapy Analytical Development & mRNA Assay Development Summits – 2023

November 27th, 2023|

We are excited to announce that Avance Biosciences™ will be attending the highly anticipated Gene Therapy Analytical Development Summit and the mRNA Assay Development Summit, and we cordially invite you to join us! As a leader in development and validation of  assays for advanced therapies...

2111, 2023

A Historic Milestone as UK Regulatory Body Approves Revolutionary CRISPR Treatment

November 21st, 2023|

In a landmark decision that could reshape the landscape of medicine and treatment, the United Kingdom has granted approval for the first-ever CRISPR therapy, Casgevy. This groundbreaking development marks a significant stride in the field of genetic medicine and opens up new possibilities for treating a range of...

3010, 2023

CRISPR-Based Therapy Analytical Development Summit – 2023

October 30th, 2023|

We are thrilled to announce that Avance Biosciences™ will be attending the highly anticipated CRISPR-Based Therapy Analytical Development Summit, and we cordially invite you to join us! As a leader in advanced therapies, we understand the importance of staying at the forefront of gene therapy innovation...

1710, 2023

Donor kidneys carrying human transgenes results in life-supporting organ function and recipient survival of over two years

October 17th, 2023|

eGenesis announced long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This dataset will support advancement of the company’s lead candidate for kidney transplant, EGEN-2784, toward clinical development...

1010, 2023

Gene therapy biotech LEXEO Therapeutics files for IPO

October 10th, 2023|

LEXEO Therapeutics will use the net proceeds from this offering to advance the clinical development of cardiac and neurological disease gene therapies. LEXEO Therapeutics, in its SEC filing, said it intends to use the net proceeds from this offering, together with their existing cash, to advance the clinical development of LX2006, LX2020 and LX1001...

Go to Top